• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   DSpace Ana Sayfası
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
  •   DSpace Ana Sayfası
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies

Tarih

2014

Yazar

Marciano, Beatriz E.
Huang, Chiung-Yu
Joshi, Gyan
Rezaei, Nima
Carvalho, Beatriz Costa
Allwood, Zoe
Orellana, Julio C.

Üst veri

Tüm öğe kaydını göster

Özet

Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). The odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. In contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001). Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.

Kaynak

Journal of Allergy and Clinical Immunology

Cilt

133

Sayı

4

Bağlantı

https://doi.org/10.1016/j.jaci.2014.02.028
https://hdl.handle.net/20.500.12712/15233

Koleksiyonlar

  • PubMed İndeksli Yayınlar Koleksiyonu [6144]
  • Scopus İndeksli Yayınlar Koleksiyonu [14046]
  • WoS İndeksli Yayınlar Koleksiyonu [12971]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Politika | Rehber | İletişim |

DSpace@Ondokuz Mayıs

by OpenAIRE

Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına Göre

Hesabım

GirişKayıt

İstatistikler

Google Analitik İstatistiklerini Görüntüle

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Politika || Kütüphane || Ondokuz Mayıs Üniversitesi || OAI-PMH ||

Ondokuz Mayıs Üniversitesi, Samsun, Türkiye
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz:

Creative Commons License
Ondokuz Mayıs Üniversitesi Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Ondokuz Mayıs:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.